EUVIMEDEUVIMED entdecken
Crossref

Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression

Cole Friedes, Nikhil Yegya-Raman, Siqi Zhang, Michelle Iocolano, Roger B Cohen, Charu Aggarwal, Jeffrey C Thompson, Melina E Marmarelis, William P Levin, Keith A Cengel, Christine A Ciunci, Aditi P Singh und 4 weitere

Clinical Lung Cancer · 2024-01 · 25 (1) · 50-60.e6

DOI: 10.1016/j.cllc.2023.09.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2024-01. Verfasst von Cole Friedes und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. Electronic address: cole.friedes@pennmedi…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The patterns of failure (POF) for metastatic non-small-cell lung cancer (mNSCLC) treated with immunotherapy are not well established. METHODS: We conducted a retrospective cohort study of mNSCLC that received first-line pembrolizumab with or without chemotherapy at a single academic center from 2015 to 2021. We defined POF with 2 classifications: 1) local, regional, or distant failure, or 2) failure in existing lesions, new lesions, or a combination. Oligoprogression was defined as disease progression (PD) in ≤3 sites of failure. Overall survival (OS) was measured via Kaplan-Meier and modelled with Cox regression. RESULTS: Of 298 patients identified, 198 had PD. Using POF classification 1, most failures were distant (43.9%) or a combination of locoregional and distant (34.4%). For POF classification 2, failures occurred in a combination of new and existing lesions (45.0%), existing lesions alone (33.3%), or in new lesions only (21.7%). Oligoprogression occurred in 39.9% (n = 79) cases. Median OS was higher in the following: PD in existing lesions vs. new or new + existing lesions (28.7 vs. 20.2 vs. 13.9 months, P < .001) and oligoprogression vs. polyprogression (35.1 vs. 12.2 months, P < .001). In oligoprogression, median OS was better for those who received radiation to all sites of PD (62.2 months) than for those who changed systemic therapy (22.9 months, P = .007). On multivariable analysis, radiation for oligoprogression (HR 0.35, 95% CI: 0.20-0.62, P < .001) was associated with improved OS. CONCLUSIONS: In mNSCLC treated with pembrolizumab, oligoprogression is relatively common. Randomized data are needed to define the benefits of radiation in oligoprogressive mNSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansRetrospective StudiesAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

LCTNSCLCOligoprogressionPembrolizumabSBRT

Substanzen

pembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. Electronic address: cole.friedes@pennmedicine.upenn.edu.
  • Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
  • Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA.
  • Division of Hematology/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
  • Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

Zitieren

APA

Friedes, C., Yegya-Raman, N., Zhang, S., Iocolano, M., Cohen, R. B., Aggarwal, C., Thompson, J. C., Marmarelis, M. E., Levin, W. P., Cengel, K. A., Ciunci, C. A., Singh, A. P., D'Avella, C., Davis, C. W., Langer, C. J., & Feigenberg, S. J. (2024). Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression. Clinical Lung Cancer, 25(1), 50-60.e6. https://doi.org/10.1016/j.cllc.2023.09.002

Vancouver

Friedes C, Yegya-Raman N, Zhang S, Iocolano M, Cohen RB, Aggarwal C, et al. Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression. Clinical Lung Cancer. 2024;25(1):50-60.e6. doi:10.1016/j.cllc.2023.09.002

BibTeX
@article{Friedes2024,
  author = {Friedes, Cole and Yegya-Raman, Nikhil and Zhang, Siqi and Iocolano, Michelle and Cohen, Roger B and Aggarwal, Charu and Thompson, Jeffrey C and Marmarelis, Melina E and Levin, William P and Cengel, Keith A and Ciunci, Christine A and Singh, Aditi P and D'Avella, Christopher and Davis, Christiana W and Langer, Corey J and Feigenberg, Steven J},
  title = {Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression},
  journal = {Clinical Lung Cancer},
  year = {2024},
  volume = {25},
  number = {1},
  pages = {50--60.e6},
  doi = {10.1016/j.cllc.2023.09.002}
}
Kostenlos starten →